Beijing Foyou Pharma (601089.SH): Pioglitazone Metformin Tablets (15mg/850mg) Obtains Drug Registration Certificate.

Beijing Foyou Pharma (601089.SH) announced that recently, the company has received the Drug Registration Certificate (certificate number: 2025S02764) for the fixed-dose combination tablet of Pioglitazone and Metformin (15mg/850mg) from the National Medical Products Administration ("NMPA"), approving the production of the drug. The innovator company of the Pioglitazone and Metformin tablet (15mg/850mg) is Takeda Pharmaceutical Company Limited, which was approved for market in the United States in August 2005. Currently, the innovator company's Pioglitazone and Metformin tablet has not been marketed in China. This product is indicated for type 2 diabetes patients who are currently being treated with a combination of Pioglitazone and Metformin or for those with inadequate blood sugar control after treatment with Metformin alone, in addition to diet and exercise control.